SCHEMBL2489746

SCHEMBL2489746

COc1ccc(Cn2ncc3c4c(cnc32)CC(NOC(=O)C(F)(F)F)CC4)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
MAPT P10636 4/20 0.39
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CNR2 P34972 3/20 0.39
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ABL1 P00519 2/20 0.36
BCR P11274 1/20 0.36
PDE1B Q01064 5/20 0.36
PDE1A P54750 4/20 0.36
PDE1C Q14123 4/20 0.36
PDE4B Q07343 2/20 0.36
PKM P14618 1/20 0.35
NPBWR1 P48145 1/20 0.35
NR3C1 P04150 1/20 0.34
ADORA1 P30542 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2491028 0.85 CNR2 (0.41) ALDH1A1MAPTLMNASMN1; SMN2CNR2
SCHEMBL12315715 0.83 LMNA (0.46) ALDH1A1MAPTLMNASMN1; SMN2CNR2
SCHEMBL2487179 0.83 LMNA (0.43) ALDH1A1MAPTLMNASMN1; SMN2CNR2
Trifluoroacetic Acid SCHEMBL2487630 0.82 CNR2 (0.40) ALDH1A1MAPTLMNASMN1; SMN2CNR2
SCHEMBL2484040 0.81 MTNR1A (0.45) ALDH1A1MAPTLMNASMN1; SMN2HPGD
SCHEMBL2490474 0.81 ALDH1A1 (0.43) ALDH1A1MAPTLMNASMN1; SMN2CNR2
SCHEMBL2484561 0.80 CYP2C19 (0.47) ALDH1A1MAPTLMNASMN1; SMN2HPGD
SCHEMBL2487707 0.79 KMT2A (0.49) ALDH1A1MAPTLMNASMN1; SMN2HPGD
SCHEMBL2486658 0.78 ALDH1A1 (0.45) ALDH1A1MAPTLMNASMN1; SMN2CNR2
SCHEMBL2486573 0.78 ALDH1A1 (0.44) ALDH1A1MAPTLMNASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
EP-2379551-A1 SUBSTITUTED PYRAZOLO [3, 4-B]PYRIDINE COMPOUNDS ArQule, Inc. (US) 2011-10-26 EP disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 ALDH1A1 460/4885MAPT 3332/4885LMNA 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.